A population-based study on the risk of prescription opioid abuse in patients with chronic opioid use and cost-effectiveness of prescription drug monitoring program using a patient simulation model in South Korea

Kim, Siin; Suh, Hae Sun

doi:10.1016/j.drugpo.2023.103953

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our results, Rice et al reported that frequent NIOA prescription was the strongest risk factor of OUD occurrence in prescription opioid users (aOR 6.85, 95% CI 5.98-7.85) (Rice et al 2012). Medical aid (adjusted hazard ratio 1.13, 95% CI 1.07-1.19) was also reported as a significant risk factor in another study in Korea (Kim and Suh 2023). Common medication classes concomitantly misused in patients with OUD are sedatives, hypnotics, or anxiolytics.…”

Section: Discussionsupporting

confidence: 92%

“…Therefore, to define the OUD case, we used www.journal-dtt.org the ICD-10 codes (F11), which had more than 90% positive predictive value (96.3%, 95% CI 90.8-98.6), although the sensitivity was moderate (42.6%, 95% CI 36.3-49.1) (Campanile and Silverman 2022). Among the known risk factors for OUD, benzodiazepine use, opioid dose, economic status, and frequent NIOA prescriptions were re-confirmed in this study (Rice et al 2012;Cragg et al 2019;Kim and Suh 2023). In line with our results, Rice et al reported that frequent NIOA prescription was the strongest risk factor of OUD occurrence in prescription opioid users (aOR 6.85, 95% CI 5.98-7.85) (Rice et al 2012).…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Incidence and Risk Factors of Opioid Use Disorder in New Users of Opioid Analgesics in Korea: Analysis of a National Claims Database

Heo,

Jo,

Noh

et al. 2023

DTT

View full text Add to dashboard Cite

Opioid analgesics are essential medications for severe pain; however, their use can cause various adverse events. Opioid use disorder (OUD) is a serious challenge associated with infectious diseases, injuries, and deaths. This study aimed to identify the incidence of OUD and its associated factors in Korean adults who were new users of non-injectable opioid analgesics (NIOA) using data from the national claims database provided by Health Insurance Review and Assessment Services from 2016 to 2018. Patients who received a new diagnosis of OUD after NIOA initiation, defined by the International Classification of Diseases-10 were classified as the case group. We used the exact match method to select a control group of patients without OUD in a 1:4 ratio. The cumulative incidence of OUD for 2 years after NIOA initiation was 0.006%. Factors associated with OUD occurrence included daily morphine milligram equivalents (≥ 50 MME/day; adjusted odds ratio [aOR] 5.04, 95% confidence interval [CI] 1.92-13.25), number of NIOA prescriptions (≥ 10; aOR 19.05, 95% CI 5.53-65.58), and use of sustained-release formulation (aOR 3.5, 95% CI 1.8-6.78). Benzodiazepine uses and type of insurance were also significantly associated with OUD occurrence. The incidence of OUD in patients using NIOA identified through diagnostic codes in Korea was lower than that in other countries. Close monitoring is recommended for patients with identified risk factors.

show abstract

Section: Discussionsupporting

confidence: 92%